首页> 美国卫生研究院文献>Springer Open Choice >Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

【2h】

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

机译：如89Zr-利妥昔单抗免疫PET所预测的在CD20 + B细胞淋巴瘤中90Y-利妥昔单抗对放射免疫疗法的肿瘤靶向和放射剂量：未加标签的利妥昔单抗的预加载的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo compare using immuno-PET/CT the distribution of ⁸⁹Zr-labelled rituximab without and with a preload of unlabelled rituximab to assess the impact of preloading with unlabelled rituximab on tumour targeting and radiation dose of subsequent radioimmunotherapy with ⁹⁰Y-labelled rituximab in CD20+ B-cell lymphoma.

机译：目的使用免疫PET / CT比较在未加和未加标签的利妥昔单抗的情况下^{89 Zr标记的利妥昔单抗的分布情况，以评估未加标签的利妥昔单抗预加载对肿瘤靶向和随后放疗的放疗剂量的影响CD20 + B细胞淋巴瘤中^{90 Y标记的利妥昔单抗。}}

著录项

期刊名称 Springer Open Choice
作者
Kristoff Muylle; Patrick Flamen; Danielle J. Vugts; Thomas Guiot; Ghanem Ghanem; Nathalie Meuleman; Pierre Bourgeois; Bruno Vanderlinden; Guus A. M. S. van Dongen; Hendrik Everaert; Mélanie Vaes; Dominique Bron;
展开▼
作者单位

展开▼
年(卷),期 -1(42),8
年度 -1
页码 1304–1314
总页数 11
原文格式 PDF
正文语种
中图分类外科学;
关键词
Radioimmunotherapy CD20+ B-cell lymphoma sup90/supY-Rituximab Rituximab preload Immuno-PET sup89/supZr-rituximab Dosimetry;

机译：放射免疫疗法;CD20 + B细胞淋巴瘤;sup 90 / sup Y-利妥昔单抗;利妥昔单抗预负荷;Immuno-PET;sup 89 / sup Zr-利妥昔单抗;剂量测定;

相似文献

外文文献
中文文献
专利

1. Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab [J] . Kristoff Muylle, Patrick Flamen, Danielle J. Vugts, European Journal of Nuclear Medicine and Molecular Imaging . 2015,第8期

机译：如89Zr-利妥昔单抗免疫PET所预测的，在CD20 + B细胞淋巴瘤中90Y-利妥昔单抗对放射免疫疗法的肿瘤靶向和放射剂量：未加标签的利妥昔单抗的预加载的影响
2. Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab [J] . Muylle Kristoff, Flamen Patrick, Vugts Danielle J., European Journal of Nuclear Medicine and Molecular Imaging . 2015,第8期

机译：Zr-89-利妥昔单抗免疫PET预测，在CD20 + B细胞淋巴瘤中使用Y-90-利妥昔单抗在放射免疫疗法中的肿瘤靶向和放射剂量：未标记利妥昔单抗预加载的影响
3. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. [J] . Illidge TM, Bayne M, Brown NS, Blood: The Journal of the American Society of Hematology . 2009,第7期

机译：在低度B细胞淋巴瘤中分级（131）I-利妥昔单抗的1/2期研究：先前给予利妥昔单抗的剂量和肿瘤负荷对后续放射免疫治疗的影响。
4. FDG-PET/CT integration: impact on tumour localization and dose volume histograms in radiation therapy [C] . Caldwell, C.B., Mah, Engineering in Medicine and Biology Society, 2000. Proceedings of the 22nd Annual International Conference of the IEEE . 2000

机译：FDG-PET / CT整合：对放射治疗中的肿瘤定位和剂量体积直方图的影响
5. Targeting X-linked Inhibitor of Apoptosis Protein to Overcome Rituximab/Chemotherapy Resistance in B-Cell Lymphomas [D] . Khan, Sumera. 2019

机译：针对凋亡蛋白的X型抑制剂，克服B细胞淋巴瘤中的Rituximab /化疗抗性
6. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL [O] . Yaya Chu, Aradhana Awasthi, Sanghoon Lee, 2020

机译：ObInutuzumab（Ga101）与Rituximab显着增强了细胞死亡抗体依赖性细胞毒性并改善了异种移植Nod-Scid IL2RGNULL（NSG）小鼠模型中的CD20 +原发性纵隔B细胞淋巴瘤（PMBL）的整体存活率：潜在的靶向剂治疗PMBL.
7. Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab [O] . Kristoff Muylle, Patrick Flamen, Danielle J. Vugts, 2015

机译：如89Zr-利妥昔单抗免疫PET所预测的，在CD20 + B细胞淋巴瘤中90Y-利妥昔单抗对放射免疫疗法的肿瘤靶向和放射剂量：未加标签的利妥昔单抗的预加载的影响

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

摘要

著录项

相似文献

相关主题

期刊订阅